Castrejón et al., 2018

Prediction of primary non-response to methotrexate therapy using demographic, clinical and psychosocial variables: results from the UK Rheumatoid Arthritis Medication Study (RAMS)

At a glance

Objective

To identify baseline variables that predict remission according to different criteria in RA

Related articles

For more articles on prediction of MTX treatment response, see Duong et al., 2022, Myasoedova et al., 2021, Sergeant et al., 2018.

Link

DOI: https://doi.org/10.3899/jrheum.141586

Background

TODO

Methods

• Analysed individual variables and indices at baseline
• Predicted remission at either 6 or 12 months according to Boolean remission, SDAI, CDAI and DAS28

Results

• Remission was predicted “significantly” (?) in 27 to 51 percent of patients
• Relevant predictors were younger age, low scores (no brainer? see also Capelusnik & Aletaha, 2021) on composites and their components, HAQ, pain, etc
• Remission was not predicted by the absence of “poor prognosis RA” (meaning “difficult to treat RA”?) or radiographic erosions
• In multivariate regressions that included only three variables (sounds like some model selection?) low HAQ predicted remission according to all criteria as effectively as SJC, ESR, or CRP

Conclusions

• Younger age and (low scores on) six core data set clinical measures predicted remission
• Absence of traditional “poor prognosis RA” indicators, RA, ACPA, or radiographic erosions did not predict remission